A Blinded Randomized Clinical Study of RefluxStop™ Compared With Nissen Fundoplication in the Treatment of GERD
- Conditions
- GERD (Gastroesophageal Reflux Disease)
- Registration Number
- NCT07004400
- Lead Sponsor
- Implantica CE Reflux Ltd.
- Brief Summary
This study will evaluate if the RefluxStop™ device will treat your acid reflux and improve your symptoms and how it compares to the standard surgical treatment for GERD, the Nissen fundoplication.
- Detailed Description
This study is a post-market prospective, blinded, randomized, multicenter, multi-arm clinical investigation using standard clinical procedures to record data to evaluate the safety and performance of RefluxStop™ compared with standard Nissen fundoplication for the treatment of subjects suffering from GERD.
A randomization will be performed where the Subjects will be blinded as to assigned randomization group.
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 200
- Willing and able to provide informed consent and to participate in the clinical investigation;
- Age ≥ 18 years or according to local legal age of adulthood at the location of the test site if older;
- Documented GERD present for ≥ 12 months. Typical symptoms are defined as heartburn, which is a burning sensation often presented as a substernal pain;
- 24-hour pH monitoring proven GERD with pH measurement, off PPI therapy for at least 7 days prior to testing. (Total distal esophageal pH must be < 4 for ≥ 4.5% of time during a 24-hour monitoring);
- Suitable to undergo general anesthesia and is a suitable laparoscopic surgery candidate as determined by the investigator
- > 8 cm sliding hernia and paraesophageal hernia; no mesh is allowed;
- Manometry verified lack of or moderate or severe weak peristalsis in esophagus with DCI <300 or pathologic LOS function including hypercontractability, spasm or pathologic nonrelaxing functionality (the latter defined as coordinated swallows in less than 70% of wet swallows or median IRP>15mmHg). Hypercontractability defined as DCI >8'000 or pressure >45 mmHg. Thus, excluding from the study the rare diseases achalasia, scleroderma, and nutcracker esophagus, however, including mild esophageal motility disorder patients with mildly weak peristalsis;
- History of bariatric or anti-reflux surgery;
- Female subjects who are pregnant or nursing;
- Known sensitivity or allergies to silicone materials;
- Intraoperative findings determined by the investigator that may result in unfavorable conduct of the clinical investigation procedure (as outlined in the IFU);
- Subjects that are unable to comply with the clinical investigation requirements (for example due to major psychiatric disorder or are considered otherwise unsuitable for participation in the clinical investigation according to the investigator's judgement);
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Patient Reported Outcomes - Side effects (PROS) evaluation 6 months Patient Reported Outcomes - Side effects (PROS) evaluation at 6 months, combining the well-established side effects of traditional surgical treatment methods:
* Dysphagia - swallowing difficulties;
* Odynophagia - pain at swallowing;
* Inability to belch and inability to vomit; and
* Worsening of gas bloating compared to baseline;
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (4)
St. Elisabethen Krankenhaus Frankfurt
🇩🇪Frankfurt, Germany
Klinikum Friedrichshafen GmbH
🇩🇪Friedrichshafen, Germany
Klinik Beau-Site Hirslanden Bern
🇨🇭Bern, Switzerland
Universitätsklinik für Allgemeinchirurgie Klinische Abteilung für Viszeralchirurgie
🇦🇹Vienna, Austria